This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zöllner, B.
Right arrow Articles by Feucht, H.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zöllner, B.
Right arrow Articles by Feucht, H.-H.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 2005, p. 2503-2505, Vol. 43, No. 5
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.5.2503-2505.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Prevalence, Incidence, and Clinical Relevance of the Reverse Transcriptase V207I Mutation Outside the YMDD Motif of the Hepatitis B Virus Polymerase during Lamivudine Therapy

B. Zöllner,1* M. Sterneck,2 K. Wursthorn,3 J. Petersen,3 M. Schröter,1 R. Laufs,1 and H.-H. Feucht1

Institute for Infectious Diseases,1 Department of Hepatobiliary Surgery,2 Department of Internal Medicine, University Hospital Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany3

Received 2 October 2004/ Returned for modification 15 November 2004/ Accepted 16 December 2004

The reverse transcriptase V207I mutation within the hepatitis B virus (HBV) polymerase is associated with resistance to lamivudine in vitro. The prevalence of this mutation in treatment-naïve patients was 1% (1/96). A follow-up of the patient carrying this mutation prior to treatment revealed no loss of sensitivity of HBV to lamivudine in vivo.

* Corresponding author. Mailing address: Institute for Infectious Diseases, University Hospital Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany. Phone: 49-40-428033159. Fax: 49-40-428034062. E-mail: zoellner{at}uke.uni-hamburg.de.

Journal of Clinical Microbiology, May 2005, p. 2503-2505, Vol. 43, No. 5
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.5.2503-2505.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Warner, N., Locarnini, S., Kuiper, M., Bartholomeusz, A., Ayres, A., Yuen, L., Shaw, T. (2007). The L80I Substitution in the Reverse Transcriptase Domain of the Hepatitis B Virus Polymerase Is Associated with Lamivudine Resistance and Enhanced Viral Replication In Vitro. Antimicrob. Agents Chemother. 51: 2285-2292 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»